Table of Contents
- What NAD+ Is and Its Role in Autoimmune Disease
- How NAD+ IV Therapy Is Administered
- Clinical Research on NAD+ and Immune Function
- NAD+ IV Therapy and Inflammation Management
- Potential Benefits for Fatigue, Joint Pain, and Symptom Relief
- NAD+ Infusion Side Effects and Safety Considerations
- NAD+ IV Therapy Cost and Access Considerations
- NAD+ IV Therapy Alongside Standard Autoimmune Treatment
- What You Need to Know Before Starting NAD+ IV Therapy
- External Resources
- Frequently Asked Questions
Last Updated: October 19, 2026
What NAD+ Is and Its Role in Autoimmune Disease
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell that powers cellular energy production and regulates immune function, making NAD+ IV therapy autoimmune disease management a topic of growing clinical interest. When NAD+ levels decline, which happens with age, chronic illness, and autoimmune activation, cells struggle to generate energy and immune regulation falters.
Autoimmune diseases occur when the immune system attacks the body’s own tissues. Conditions like rheumatoid arthritis, lupus, and other chronic inflammatory disorders involve both excessive immune activation and impaired immune regulation. The inflammatory response produces cytokines and other signaling molecules that drive joint pain, systemic inflammation, and fatigue.
NAD+ metabolism and cellular energy production
NAD+ functions as an electron carrier in mitochondria, the cell’s power plant.
As NAD+ levels drop, mitochondrial efficiency declines. This energy deficit is especially problematic in autoimmune fatigue, where patients report profound tiredness despite rest.
NAD+ metabolism is also linked to cellular repair and DNA repair mechanisms. Sirtuins and PARPs, two families of NAD+-dependent enzymes, regulate stress responses and DNA damage repair.
How NAD+ regulates immune function and inflammatory response
Beyond energy production, NAD+ directly regulates immune cell behavior through signaling pathways. Sirtuins, NAD+-dependent deacetylases, suppress inflammatory gene expression in immune cells.
NAD+ also influences T-regulatory cells (Tregs), which suppress autoimmune responses. Animal studies suggest that NAD+ availability affects Treg differentiation and function.
The inflammatory pathways in autoimmune disease involve cytokine signaling, particularly pro-inflammatory cytokines like TNF-alpha and IL-6.
NAD+ is essential for mitochondrial energy production and immune regulation. Autoimmune diseases involve both energy depletion and immune dysregulation, creating a theoretical rationale for NAD+ restoration, but human evidence is still emerging.
How NAD+ IV Therapy Is Administered
NAD+ IV therapy involves intravenous infusion of NAD+ directly into the bloodstream, bypassing the gastrointestinal tract.
Dosing protocols vary widely across clinics. There is no standardized clinical protocol for NAD+ IV therapy autoimmune disease treatment, which means dosing is largely empirical and clinic-dependent.
Intravenous infusion protocols and dosing
The typical infusion appointment lasts 1-3 hours, depending on the infusion rate and total dose. Slower infusions (over 2-3 hours) are often used to minimize side effects.
Monitoring during infusion is minimal in most outpatient settings. Blood pressure and heart rate may be checked before and after. Patients are usually advised to remain hydrated and rest for several hours after the infusion.
Why IV delivery differs from oral supplementation and bioavailability
Oral NAD+ supplements have extremely poor bioavailability. NAD+ is a large, polar molecule that cannot cross the intestinal barrier efficiently.
Intravenous delivery bypasses this absorption problem entirely. NAD+ infused directly into the bloodstream achieves immediate, high circulating levels.
The half-life of circulating NAD+ is short, minutes to hours. This means NAD+ infusions produce transient elevation of blood NAD+, not sustained restoration.
NAD+ infusions achieve high circulating levels briefly, but the clinical significance of this transient elevation in autoimmune disease is unproven. Do not assume that a high blood NAD+ level during or immediately after infusion translates to lasting therapeutic benefit.
Clinical Research on NAD+ and Immune Function
The evidence base for NAD+ IV therapy in autoimmune disease is limited. Most research is preclinical, conducted in cell cultures or animal models, rather than clinical trials in humans.
Preclinical studies show that NAD+ and its precursors reduce inflammatory cytokine production in immune cells and enhance Treg function in mouse models of autoimmune disease. Some animal studies report reduced disease activity when NAD+ levels are restored.
What preclinical studies show about NAD+ and autoimmune pathways
Laboratory studies demonstrate that NAD+-dependent sirtuins suppress pro-inflammatory signaling in T cells and macrophages.
Animal models of autoimmune arthritis, lupus, and other conditions show that NAD+ precursors or sirtuin activators reduce disease severity, joint inflammation, and systemic inflammatory markers.
However, animal models are imperfect predictors of human responses. Mice are inbred, genetically uniform, and lack the complexity of human immune systems and comorbidities.
Current clinical evidence limitations and evidence quality
As of 2026, there are no large, randomized controlled trials (RCTs) of NAD+ IV therapy specifically for autoimmune disease.
Without RCTs, it is impossible to know whether NAD+ infusions truly reduce autoimmune inflammation or whether observed improvements reflect placebo effect, regression to the mean, or concurrent changes in other treatments.
The evidence quality for NAD+ IV therapy in autoimmune disease is low. This does not mean the therapy is ineffective, it means the evidence is insufficient to determine effectiveness.
Preclinical research shows NAD+ can reduce inflammation in laboratory settings and animal models, but human clinical trials are absent. Current clinical evidence for NAD+ IV therapy in autoimmune disease is limited to small observational studies and case reports, which are insufficient to establish efficacy.
NAD+ IV Therapy and Inflammation Management
The inflammatory pathways in autoimmune disease involve multiple layers of immune activation: antigen recognition, T cell and B cell proliferation, cytokine production, and tissue infiltration. NAD+ could theoretically intervene at multiple points, but the evidence for clinical benefit remains speculative. The most useful way to read that evidence is disease by disease, and by study type, because the strength of the case is very different for rheumatoid arthritis than for lupus, Sjögren’s, scleroderma, or inflammatory bowel disease.
How NAD+ affects inflammatory pathways and cytokine production
NAD+-dependent sirtuins suppress NF-kB signaling, a central hub of pro-inflammatory gene expression.
Additionally, NAD+ supports PARP activity, which regulates DNA repair and stress responses.
NAD+ also affects immune cell metabolism. Immune cells shift between glycolytic and oxidative metabolism depending on their activation state.
A key distinction: these are mechanistic findings from cell cultures and animal models. They show that NAD+ biology is connected to inflammatory pathways.
Disease-specific considerations: rheumatoid arthritis, lupus, and other autoimmune conditions
Rheumatoid arthritis is characterized by persistent joint inflammation, elevated TNF-alpha and IL-6, and progressive joint destruction.
Systemic lupus erythematosus (SLE) involves widespread autoimmunity affecting skin, joints, kidneys, and other organs. The pathophysiology includes aberrant B cell activation, immune complex deposition, and complement activation.
Other autoimmune conditions each have distinct pathophysiology. Blanket claims that NAD+ IV therapy helps “autoimmune disease” ignore these differences.
Grading the evidence: what study type tells you
It helps to sort the evidence into tiers, because the tiers carry very different weight:
- Cell-culture studies show that NAD+ and NAD+-dependent enzymes influence inflammatory signaling in isolated cells. They establish biological plausibility only.
- Animal models show that NAD+ precursors or sirtuin activators can reduce disease severity in some induced and genetic models. Animal models are imperfect predictors of human response: mice are inbred, genetically uniform, and lack the complexity of human immune systems and comorbidities.
- Small observational studies and case reports in humans describe patients who reported symptom improvement. These lack control groups, blinding, and objective disease-activity measures, so they cannot distinguish true effect from placebo, regression to the mean, or concurrent treatment changes.
A second distinction matters just as much: a change in a lab measurement is not the same as a clinical benefit. An infusion may raise circulating NAD+ for a few hours, or shift a marker in a research assay, without changing disease activity scores, joint counts, fatigue, or function. When you read or hear claims about NAD+ and autoimmune disease, ask which tier the evidence comes from and which outcome actually changed.
What outcomes would actually matter
If NAD+ therapy were to be evaluated properly in autoimmune disease, the outcomes that would count are the ones rheumatologists already use: validated disease activity scores (for example, DAS28 or CDAI in rheumatoid arthritis, and SLEDAI in lupus), inflammatory markers such as CRP and ESR, patient-reported fatigue and function measures, flare frequency, and adverse events. Subjective “I feel better” reports are meaningful to the patient but are not the same as demonstrated efficacy, and placebo effects in autoimmune disease can be substantial, especially for fatigue and pain.
NAD+ IV therapy is sometimes marketed as a treatment for multiple autoimmune conditions, but disease-specific clinical evidence does not exist. Different autoimmune diseases have distinct pathophysiology, and a mechanism shown in one disease does not necessarily apply to others. Do not stop or reduce prescribed immunomodulators or biologics to try NAD+ therapy.
Potential Benefits for Fatigue, Joint Pain, and Symptom Relief
Fatigue is one of the most burdensome symptoms in autoimmune disease, often persisting despite adequate disease control with standard medications. This gap has created interest in adjunctive therapies like NAD+ that might address energy production.
Joint pain in autoimmune arthritis involves both inflammatory cytokine-mediated nociception and structural joint damage. NAD+-dependent cellular repair mechanisms could theoretically reduce pain by supporting tissue healing, but clinical evidence is lacking.
Energy production and mitochondrial function in autoimmune fatigue
Autoimmune fatigue reflects genuine cellular energy depletion. Immune activation consumes energy, and chronic inflammation increases metabolic demand on tissues.
NAD+ is essential for mitochondrial ATP synthesis. In theory, restoring NAD+ would improve ATP production and reduce fatigue. Some patients report improved energy after NAD+ infusions, though these reports are anecdotal.
fatigue in autoimmune disease has multiple causes: active inflammation, medication side effects, sleep disruption, deconditioning, and psychological factors.
Cellular repair, DNA repair, and oxidative stress reduction
Chronic autoimmune inflammation generates oxidative stress, producing reactive oxygen species (ROS) that damage cellular components, including DNA.
Theoretically, maintaining adequate NAD+ levels supports these repair pathways, reducing accumulation of oxidative damage and potentially slowing tissue aging.
The oxidative stress in autoimmune disease is driven by active inflammation. Reducing inflammation, through conventional immunosuppressive therapy, is the most direct way to reduce oxidative stress.
NAD+ Infusion Side Effects and Safety Considerations
NAD+ IV infusions are generally well-tolerated in healthy people, but side effects do occur, and the safety picture is less clear in people with autoimmune disease who take immunomodulating medications. Understanding these risks, and screening for them before the first infusion, is important for informed decision-making.
Common side effects during and after IV infusion
The most common side effect is flushing, a sensation of warmth and redness, typically mild and self-limited. Some patients report nausea, headache, or dizziness during infusion.
A subset of patients experience a “detoxification” or “Herxheimer-like” reaction, characterized by fatigue, body aches, and malaise for 24-48 hours after infusion. The biological basis for this reaction is unclear and may reflect placebo effect or nonspecific inflammatory response to the infusion. Some clinics advise patients to expect this reaction, which can amplify expectancy effects.
Injection site reactions, pain, redness, or inflammation at the IV site, occur occasionally, especially if the IV is placed in a small vein or the infusion is rapid. Proper IV technique minimizes this risk.
Contraindications, medication interactions, and who should avoid NAD+ therapy
NAD+ therapy is generally avoided in patients with acute infection, unstable cardiac arrhythmias, or severe renal disease.
Medication interactions are a key concern. Many autoimmune patients take immunosuppressants, biologics, corticosteroids, or other medications that affect immune function or metabolism. Whether NAD+ infusions interact with these drugs is largely unknown, safety data on NAD+ combined with most autoimmune medications is sparse.
A clinician-review checklist before your first infusion
Use this checklist as a conversation guide with both your rheumatologist and the provider administering the infusion. It is not a substitute for medical evaluation.
- Autoimmune diagnosis and current disease activity: Which condition(s) do you have, and is disease currently active, flaring, or in remission? Active flares are a reason to prioritize standard therapy review first.
- Current medications: List every immunosuppressant, biologic, corticosteroid, DMARD, and over-the-counter supplement. Ask specifically whether any interaction with NAD+ is known or plausible.
- Comorbidities: History of gout or elevated uric acid, kidney disease, liver disease, cardiac arrhythmia, active infection, or cancer. Each of these changes the risk-benefit calculation.
NAD+ infusions have not been studied in combination with most autoimmune medications. If you are taking immunosuppressants, biologics, or other medications, discuss NAD+ therapy with your rheumatologist or prescribing physician before starting. Do not assume that NAD+ is safe to combine with your current medications, and do not stop prescribed autoimmune medications to try it.
NAD+ IV Therapy Cost and Access Considerations
NAD+ IV therapy is not covered by most insurance plans and is typically out-of-pocket. Pricing varies widely depending on location, clinic, and infusion protocol. At Ascend Vitality, NAD+ infusions are offered as part of broader optimization programs, though specific pricing depends on your individual program and location.
Pricing structure and what affects treatment costs
The cost of a single NAD+ infusion varies based on several factors: the dose administered, the infusion duration, the clinic’s overhead, and whether the infusion is combined with other IV therapies.
Treatment frequency also affects total cost. If a clinic recommends weekly infusions for 8 weeks followed by monthly maintenance, the cumulative cost can reach thousands of dollars annually.
Insurance coverage and out-of-pocket considerations
NAD+ IV therapy is considered experimental or elective by most insurance companies and is not covered. Medicare does not cover NAD+ infusions for autoimmune disease.
The lack of insurance coverage means NAD+ therapy is accessible primarily to patients with disposable income.
Before pursuing NAD+ IV therapy, carefully consider the cost and whether the potential benefits justify the expense.
NAD+ IV Therapy Alongside Standard Autoimmune Treatment
Most patients with autoimmune disease are treated with conventional medications: corticosteroids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) like methotrexate, or biologic agents like anti-TNF therapies. The question of whether NAD+ IV therapy should be combined with these treatments is important.
Integration with anti-TNF therapy and conventional medications
Anti-TNF agents and other biologics are highly effective at reducing inflammation and preventing disease progression in autoimmune arthritis and other conditions. These medications work by blocking specific inflammatory pathways.
Whether NAD+ provides additive benefit on top of anti-TNF therapy is unknown. No clinical trials have evaluated this combination. Some clinics market NAD+ as a “complement” to conventional therapy, but this is speculative.
Treatment protocols and medical monitoring
If you pursue NAD+ IV therapy while on autoimmune medications, close monitoring is essential.
Some clinics recommend checking baseline NAD+ levels before starting therapy, though the clinical utility of this is unclear. NAD+ levels fluctuate throughout the day and are influenced by many factors.
Monitor for medication interactions. If you are on immunosuppressants or biologics, discuss any new supplements or infusions with your prescribing physician.
If you are considering NAD+ IV therapy alongside conventional autoimmune treatment, ask your rheumatologist to help you establish clear outcome measures: specific symptoms or inflammatory markers you expect to improve. This makes it easier to determine whether NAD+ is actually helping or whether you are experiencing placebo effect or natural disease fluctuation.
What You Need to Know Before Starting NAD+ IV Therapy
Deciding whether to pursue NAD+ IV therapy requires careful consideration of the evidence, costs, and your individual situation. Here are key questions to ask before starting.
Questions to ask your healthcare provider
-
What is the evidence that NAD+ IV therapy will help my specific autoimmune condition? Ask your provider to cite clinical trials or strong evidence. If they cannot, understand that you are pursuing a treatment with limited clinical evidence.
-
How does NAD+ IV therapy fit into my current treatment plan? Discuss whether NAD+ is intended to replace, complement, or supplement your current medications. Understand the rationale for adding NAD+ specifically to your regimen.
-
What outcomes should I expect, and how will we measure them? Ask for specific, measurable goals: Will NAD+ reduce joint pain by a certain amount? Improve fatigue on a specific scale? Reduce inflammatory markers? Establish clear metrics before starting therapy.
-
Are there any medication interactions I should know about? Discuss your current medications with the provider offering NAD+ therapy. Ensure they are aware of all supplements, medications, and treatments you are taking.
-
What are the side effects, and how common are they? Understand both common side effects (flushing, nausea) and rare serious events. Ask about the clinic’s experience with adverse events.
-
How long should I continue NAD+ therapy before reassessing? Discuss a timeline for evaluation. How many infusions will you receive before determining whether the therapy is helping? What will trigger a decision to stop?
-
What is the total cost, and what is your refund or satisfaction policy? Understand the full financial commitment. Ask whether the clinic offers any guarantee or refund if you are unsatisfied.
Informed consent and realistic outcome expectations
NAD+ IV therapy is not a proven treatment for autoimmune disease.
Realistic expectations matter. NAD+ infusions are unlikely to eliminate autoimmune disease or replace conventional medications.
NAD+ might help with specific symptoms like fatigue or energy, though this is not guaranteed.
At Ascend Vitality, we help patients navigate treatment decisions with careful medical oversight.
NAD+ IV therapy represents an intriguing intersection of cellular biology and autoimmune disease management, but the clinical evidence remains preliminary.
| Consideration | Key Points |
|---|---|
| Evidence Base | Preclinical research promising; human clinical trials absent; current evidence quality is low |
| Mechanism | NAD+ supports mitochondrial energy, sirtuins, and immune regulation; theoretical benefit in autoimmune inflammation |
| Common Side Effects | Flushing, nausea, headache, fatigue; usually mild and self-limited |
| Cost | Out-of-pocket; not covered by most insurance; varies by clinic and infusion protocol |
| Best For | Patients with autoimmune fatigue or joint pain who have optimized conventional therapy and seek adjunctive options |
| Caution | Limited safety data combined with autoimmune medications; medication interactions not well-characterized |
| Realistic Outcome | Possible symptom improvement; unlikely to replace conventional autoimmune medications |
External Resources
For additional information on autoimmune disease management and current treatment guidelines, consult these authoritative sources:
American College of Rheumatology clinical practice guidelines for autoimmune disease management
Mayo Clinic overview of autoimmune disease diagnosis and treatment options
Frequently Asked Questions
Can NAD+ IV therapy help with autoimmune disease symptoms like fatigue and joint pain?
NAD+ may support energy production and cellular repair, which are often compromised in autoimmune conditions. Some patients report reduced fatigue and improved symptom management, but clinical evidence specific to autoimmune diseases remains limited. NAD+ IV therapy should complement, not replace, standard treatments prescribed by your rheumatologist or immunologist. Discuss realistic expectations with your healthcare provider before beginning.
What are the main NAD+ infusion side effects I should expect?
Common side effects during NAD+ IV infusion include flushing, nausea, mild headache, and a warm sensation at the infusion site. Most side effects are temporary and resolve shortly after the infusion ends. Rare but serious reactions can occur. Tell your provider about any medications or supplements you take, as NAD+ may interact with certain drugs. Stop the infusion and seek medical attention if you experience chest pain, difficulty breathing, or severe allergic symptoms.
Is NAD+ IV therapy FDA-approved for treating autoimmune diseases?
NAD+ IV therapy is not FDA-approved as a treatment for autoimmune disease. The FDA has not granted approval for NAD+ for any specific disease indication. Clinics offering NAD+ IV therapy do so as off-label treatment, meaning doctors use it based on emerging research and clinical judgment rather than regulatory approval. This underscores the importance of consulting a qualified healthcare provider to understand the evidence, risks, and whether it fits your individual treatment plan.
How much does NAD+ IV therapy cost, and does insurance cover it?
NAD+ IV therapy pricing depends on the infusion protocol, dosage, frequency, and the clinic’s location and credentials. Most insurance plans do not cover NAD+ IV therapy for autoimmune disease, as it lacks FDA approval and robust clinical evidence. Treatment is typically out-of-pocket. For current pricing and payment options, contact a provider directly or visit Ascend Vitality’s website for a personalized quote.
Can I use NAD+ IV therapy if I’m already on autoimmune medications like anti-TNF drugs?
NAD+ IV therapy may be used alongside conventional autoimmune treatments, but you must inform your healthcare provider of all medications and supplements you take. Some drugs can interact with NAD+ or affect how your body processes it. Your doctor will assess whether combining treatments is safe and appropriate for your specific condition and medication regimen. Never start NAD+ therapy without explicit approval from the physician managing your autoimmune disease.
What does the clinical research actually say about NAD+ and autoimmune disease?
Most research on NAD+ and immune function comes from preclinical (laboratory and animal) studies showing NAD+ influences inflammatory pathways, cytokine production, and cellular repair. Human clinical trials specifically testing NAD+ IV therapy for autoimmune diseases are limited. The evidence suggests plausible biological mechanisms, but clinical proof of effectiveness in humans with autoimmune conditions remains incomplete. This gap between mechanism and clinical benefit is why NAD+ therapy is still considered experimental for autoimmune management.
Who should not receive NAD+ IV therapy?
People with certain medical conditions, allergies, or medications may need to avoid NAD+ IV therapy. Contraindications can include uncontrolled high blood pressure, severe kidney or liver disease, certain psychiatric medications, and pregnancy. If you have a history of allergic reactions to infusions, cardiac arrhythmias, or are taking blood thinners or other medications, discuss these with your provider before starting therapy. A thorough medical review is essential to identify potential risks specific to your health profile.
